Life Sciences + Health

Leaders in Medical Translation in 250+ Languages

Evaluating Geographical Clinical Trial Trends with Dr. Vladimir Misik

In our fourth podcast episode, CSOFT CEO Ms. Shunee Yee and special guest Dr. Vladimir Misik sat down to discuss the shifting clinical trial landscape and future predictions for industry investment and market share.

MACHINE TRANSLATION FOR THE LIFE SCIENCE INDUSTRIES: THE MYTH AND THE TRUTH

Our Newest White Paper explores how the rapid development of AI technology and machine learning have provided the translation industry with new capabilities in machine translation (MT), particularly for the life science sector. Learn about the different kinds of MT as well as its potential benefits and limitations across the life sciences industries in facilitating cheaper and faster turnaround times for translation projects, without sacrificing quality.

An Interview with Vladimir Misik: What Clinical Trial Market Will Remain Competitive?

CSOFT Health Sciences sat down with Dr. Vladimir Misik to continue discussions from our latest podcast episode and explore in-depth the nature of clinical trial industry investment and evaluate global market trends.

BeiGene’s BLA for Tislelizumab Accepted for Review by FDA

The US FDA has accepted for review BeiGene’s Biologics License Application (BLA) for its anti-PD-1 antibody tislelizumab to treat patients with reoccurring locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Are you looking for an industry outside of the Life Sciences?

We are dedicated to industry-standard knowledge and quality

Helping You Globalize the Right Way

CSOFT’s experienced and dedicated global regulatory submission specialists help companies comply with these demanding multilingual documentation requirements for submissions while providing the highest linguistic quality

We can help you attain the appropriate, accurate, and sustainable compliance required throughout the entire submission process. We ensure our clients receive the necessary certifications to successfully enter emerging markets.

Medical Translation with a Focus on Precision

Our translation solutions are intended for document types relating to every stage of product development life cycle.

Quality in translation is extremely important, but within the life sciences industry, incorrect translations could literally be life threatening. We use industry-standard processes, however, we also offer flexibility for each customer to allow for their companies’ success, no matter the process.

 

Industries We Serve

Who We Are

CSOFT Health Sciences, leaders in medical translation, provides end-to-end medical translations for all phases of the product lifecycle, from pre-clinical to post-launch. We also specialize in market access consulting, medical writing, and CTD/eCTD submissions with the FDA, EMA, and NMPA.

Our operations are compliant with ISO 17100 and certified in ISO 9001:2015 and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of global submissions.

The Power of Linguistic Expertise

Right Tools. Right Resources

Tools we use

We use a full range of CAT tools including Trados, MemoQ, Transifex, Smartling, and WordServer and translate all document types, including .ai, .doc, .pdf, .ppt, .xlx, .css, .php, .html, .xml, .mml, .txt, .mpg, .mov, .zip, .psd, and more.

Learn More

Linguists we hire

Our native in-country subject-matter experts with at least 7 years’ experience go through a rigorous certification process and are guided with customer experience surveys

Learn More

Methodologies we employ

We employ a full range of customized solutions, including translation memory, glossary and style guides, PLLP, and more.

Learn More

Start Your Global Journey

    Headquarters

    501 Boylston Street, 10th Floor
    Boston, MA 02116

    Phone

    The Knowledge Vault

    Stay in the know

    For many years, CSOFT has been supporting the life science industries as they continue to grow. We are dedicated to providing the highest-quality services to our clients, while making sure they have access to different policies and up-to-date information. As a medical communications company, we are taking the initiative to promote and increase awareness in the science community and to every individual.

    MS: EMA Committee Supports Diroximel Fumarate Approval
    MS: EMA Committee Supports Diroximel Fumarate Approval

    European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced their approval of diroximel fumarate (Vumerity, Biogen Inc) for adults diagnosed with relapsing-remitting multiple sclerosis (MS). Although Diroximel fumarate is...